Hospital
Steward HH. INC.
Steward HH. INC. was paid $5.16M by Medicaid between Aug 2021 and Dec 2024, across 146 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoSTEWARD HH. INC.
HIALEAH, FL 33013
HIALEAH, FL 33013
33aNPI1396317137assigned 07/12/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.16M
24GClaims224,234
24DCodes billed146
24AFirst – last monthAug 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#81 of 163
Median peer was paid$4.77M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 34,593 | $914K | |
| 2022 | 75,170 | $1.89M | |
| 2023 | 67,747 | $1.57M | |
| 2024incomplete | 46,724 | $779K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 10,441 | 9,157 | $1.11M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 6,407 | 5,882 | $715K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 8,520 | 6,084 | $695K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 13% | 1,780 | 1,468 | $676K |
| 70450 | Computed tomography, head or brain; without contrast material | 8.3% | 1,610 | 1,368 | $428K |
| 80053 | Comprehensive metabolic panel | 6.2% | 13,217 | 7,362 | $318K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.6% | 511 | 471 | $287K |
| G0378 | Hospital observation service, per hour | 4.5% | 6,535 | 2,351 | $233K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.6% | 2,861 | 2,542 | $132K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.5% | 274 | 235 | $129K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 778 | 639 | $74K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.4% | 598 | 207 | $73K |
134 more codes
| 72131 | 1.3% | 220 | $67K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,949 | $24K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 208 | $16K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 147 | $15K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,545 | $10K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 1,558 | $10K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 843 | $9K |
| 71250 | <1% | 62 | $9K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 221 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,145 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,757 | $8K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 668 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 332 | $8K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 18 | $8K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,235 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,330 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,025 | $5K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,215 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,048 | $5K |
| 81001 | <1% | 6,922 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 608 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,589 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,748 | $3K |
| 84703 | <1% | 2,522 | $2K | |
| 81025 | <1% | 3,363 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 398 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 52 | $2K |
| 84484 | <1% | 4,666 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,479 | $2K |
| 76830 | Ultrasound, transvaginal | <1% | 76 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,047 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,407 | $1K |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 42 | $1K |
| 85610 | <1% | 3,336 | $992.14 | |
| 84702 | <1% | 1,087 | $977.68 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 101 | $972.85 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,889 | $956.67 |
| 85730 | <1% | 2,611 | $756.01 | |
| 87070 | <1% | 1,233 | $719.12 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,236 | $665.92 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 117 | $662.21 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,922 | $655.65 |
| A9270 | Non-covered item or service | <1% | 733 | $506.22 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,069 | $475.90 |
| 83735 | <1% | 4,603 | $384.45 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 564 | $383.60 |
| 73130 | <1% | 117 | $359.97 | |
| 76770 | <1% | 16 | $344.91 | |
| 82962 | <1% | 3,309 | $332.73 | |
| 70486 | <1% | 14 | $301.49 | |
| 83690 | <1% | 2,233 | $292.64 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 693 | $287.88 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 15 | $284.15 |
| 97166 | <1% | 28 | $274.83 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 136 | $266.94 |
| 87186 | <1% | 685 | $262.35 | |
| 90715 | <1% | 245 | $260.10 | |
| 84100 | <1% | 4,342 | $239.71 | |
| S0030 | Injection, metronidazole, 500 mg | <1% | 189 | $225.15 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 170 | $193.43 |
| 82550 | <1% | 1,344 | $190.69 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,084 | $189.58 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 790 | $188.23 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 417 | $179.26 |
| 73610 | <1% | 140 | $172.39 | |
| 94664 | <1% | 146 | $167.14 | |
| 97162 | <1% | 14 | $161.41 | |
| 86850 | <1% | 737 | $150.98 | |
| 86901 | <1% | 807 | $147.57 | |
| 86900 | <1% | 806 | $146.96 | |
| 73630 | <1% | 149 | $144.41 | |
| 76801 | <1% | 154 | $133.56 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 490 | $130.39 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 322 | $118.15 |
| 93970 | <1% | 17 | $113.25 | |
| 73562 | <1% | 86 | $107.64 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 748 | $107.12 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,053 | $107.12 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 151 | $105.36 |
| 83880 | <1% | 648 | $79.20 | |
| 73030 | <1% | 118 | $76.45 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 547 | $73.18 |
| 73110 | <1% | 14 | $72.74 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,259 | $68.06 |
| 82803 | <1% | 174 | $59.67 | |
| 87077 | <1% | 498 | $55.16 | |
| 87040 | <1% | 1,416 | $53.73 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 752 | $50.83 |
| 36600 | <1% | 42 | $43.22 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 123 | $42.18 |
| 81003 | <1% | 888 | $40.67 | |
| 83605 | <1% | 934 | $38.09 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 760 | $34.70 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13 | $33.34 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 97 | $22.50 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 413 | $17.25 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 516 | $17.25 |
| 80076 | <1% | 183 | $2.67 | |
| 81015 | <1% | 20 | $2.08 | |
| 87147 | 0% | 13 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 64 | $0.00 |
| 82607 | 0% | 16 | $0.00 | |
| 85027 | 0% | 58 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 195 | $0.00 |
| 85379 | 0% | 147 | $0.00 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 78 | $0.00 |
| 93971 | 0% | 13 | $0.00 | |
| 82728 | 0% | 53 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 35 | $0.00 |
| 88304 | 0% | 103 | $0.00 | |
| 83615 | 0% | 19 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 19 | $0.00 |
| 86140 | 0% | 18 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 255 | $0.00 |
| A4215 | Needle, sterile, any size, each | 0% | 32 | $0.00 |
| 87205 | 0% | 164 | $0.00 | |
| 36410 | 0% | 19 | $0.00 | |
| 76819 | Fetal biophysical profile; without non-stress testing | 0% | 22 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 13 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 12 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 86 | $0.00 |
| 86738 | 0% | 15 | $0.00 | |
| 80047 | 0% | 27 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 481 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 236 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 729 | $0.00 |
| 85007 | 0% | 32 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 503 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 138 | $0.00 |
| 82805 | 0% | 16 | $0.00 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 21 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 28 | $0.00 |
| 80061 | Lipid panel | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOLTZ, HERBERT (OFFICER, DIRECTOR, GENERAL COUNSEL)
| Provider | Location | Paid |
|---|---|---|
| Steward NSMC, INC. | Miami, FL | $5.76M |
| Steward PGH, INC. | Hialeah, FL | $5.50M |
| Steward NSMC, INC. | Lauderdale Lakes, FL | $3.53M |
| Steward CGH, INC. | Coral Gables, FL | $2.40M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.